Moberg Pharma announces plans to develop BUPI through phase III

STOCKHOLM, March 22, 2015. Moberg Pharma AB (OMX: MOB) today announced a
decision to initiate development of BUPI through phase III. The decision follows
an evaluation of the complete data set from the recent phase II study for BUPI.
BUPI is a patent pending lozenge formulation of bupivacaine for pain management
in oral mucositis in cancer patients. Following positive phase II results, the
board has approved a de-risked strategy to continue development through phase
III, including one phase III trial to be conducted in Europe co-funded by a
grant from Eurostars. A second phase III study will be conducted in India and
financed by Moberg’s partner Cadila Pharmaceuticals.

The evaluation of the complete data set from the Phase II study supports the
efficacy and safety of BUPI. Key findings include:

  · The primary endpoint was met with high statistical significance. The primary
endpoint was a measurement of pain in the mouth or pharynx, 60 minutes post
administration of BUPI, compared to the average pain during the day for the
control group. The group treated with BUPI had 31% reduction in pain compared to
the control group (VAS* 35.14 in BUPI vs. 50.94 in control, p=0.0032). Both
groups were allowed to use standard treatment options for pain during the study.
The control group was furthermore allowed to use locally acting anesthetics for
the oral cavity, in the form of a lidocaine gel.
  · When the effect in the mouth, excluding the pharynx, was measured, the
difference between the groups was even more pronounced. Treatment with BUPI
resulted in an additional pain reduction of 50% compared to standard treatment
(VAS* 17.93 vs. 36.10, p=0.0002).
  · Compared to pain at baseline (Average VAS = 58), patients on BUPI treatment
had substantially lower pain during the study period (Average VAS = 35).
  · BUPI provided meaningful pain relief until the next administration of a
lozenge. On average, the patients used
3-4 lozenges per day.
  · No serious adverse events were reported among the patients treated with
BUPI.

* Pain evaluation with VAS (visual analogue scale) where VAS 0 = no pain and VAS
100 = worst imaginable pain.
   NOTE: The positive effect of BUPI is slightly higher than previously
announced topline results due to correction
   and final evaluation of the complete data set.

About Oral Mucositis and BUPI
Oral mucositis (“OM)” is a painful inflammation and ulceration of the mucous
membranes lining the mouth. OM is a common and often debilitating complication
of cancer treatment which affects 80% of patients with head and neck cancer
receiving radiotherapy, almost all patients undergoing bone marrow
transplantation, and a wide range of patients receiving chemotherapy. OM makes
the patient less likely to comply with their cancer treatment, increases
mortality and morbidity and contributes to rising health care costs. In the
U.S., every year approximately 400 000 patients suffer from OM during cancer
therapy. The patent pending BUPI technology encompasses novel lozenge
formulations of bupivacaine, a local anesthetic with a well-established long
acting effect, currently available on the market for other indications as an
injectable.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 8.30 am (CET) on March 22, 2016.
For additional information, please contact:
Peter Wolpert, CEO, Phone: +46 (0)70 - 735 71 35, E-mail:
peter.wolpert@mobergpharma.se
Kjell Rensfeldt, VP R&D and Chief Medical Officer, Phone: + +46 8 522 307 07,
Email: kjell.rensfeldt@mobergpharma.se
About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
OTC sales operations in the U.S. and a distributor network in more than 40
countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal
Nail®, Balmex®, Domeboro®. Kerasal Nail® (Emtrix® or Nalox™ in certain markets)
is a leading OTC treatment of nail disorders in the U.S., Canada and several EU
markets and is currently being launched in Southeast Asia. The company is
growing organically as well as through acquisitions. Internal development
programs focuses on innovative drug delivery of proven compounds and include two
clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral
mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the
company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic
Exchange Stockholm (OMX: MOB).